IEC 2023 | Meaningful outcomes in epilepsy trials

Amber Freed, Founder & CEO of SLC6A1 Connect, discusses meaningful outcomes in epilepsy studies. As a parent and an advocate, Ms Freed emphasizes that a meaningful outcome should be classified as what helps patients and their loved ones in their daily lives. Currently, trial endpoints tend to include EEG measurements and seizure frequency, however these outcomes are evolving to center more around quality of life (QoL) and daily functioning. This interview took place at the International Epilepsy Congress 2023 in Dublin, Ireland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.